Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment
Key takeaways
- On June 15, Grifols launched FESILTY in the US for treating acute bleeding in pediatric and adult patients with congenital fibrinogen deficiency/CFD, excluding dysfibrinogenemia.
- Compared to traditional options like cryoprecipitate or fresh frozen plasma, FESILTY allows for faster, more predictable dosing without needing large-volume infusions or cross-matching.
- FDA approval for this therapy was supported by Phase I/III clinical study data, which confirmed its safety, pharmacokinetic properties, and hemostatic efficacy.
Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment Maham Fatima Fri, June 19, 2026 at 11:52 PM GMT+7 1 min read GRFS Grifols (NASDAQ:GRFS) is one of the top value stocks to buy under $10. On June 15, Grifols launched FESILTY in the US for treating acute bleeding in pediatric and adult patients with congenital fibrinogen deficiency/CFD, excluding dysfibrinogenemia. This highly purified human-derived fibrinogen concentrate provides a precise, targeted treatment for a rare genetic condition where insufficient clotting proteins compromise wound healing.
Compared to traditional options like cryoprecipitate or fresh frozen plasma, FESILTY allows for faster, more predictable dosing without needing large-volume infusions or cross-matching. It comes in a complete kit that can be stored at room temperature and reconstituted in approximately three minutes, making it effective for time-sensitive bleeding events.
FDA approval for this therapy was supported by Phase I/III clinical study data, which confirmed its safety, pharmacokinetic properties, and hemostatic efficacy. While effective, the product carries risks, including potential hypersensitivity and thrombotic events, and is contraindicated in patients with severe hypersensitivity to its components.